Corcept shareholders approve 8M-share increase to 2024 Incentive Award Plan

CORCEPT THERAPEUTICS INC

Stockholders approved amendment to 2024 Incentive Award Plan, adding 8,000,000 authorized shares.
All eight director nominees elected; vote totals show majority support for each.
Ernst & Young ratified as independent auditor for fiscal 2026.
Advisory vote on named executive officer compensation passed with 72.5 million 'for' votes.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CORCEPT THERAPEUTICS INC shareholders approved Election of eight directors to hold office until 2027 annual meeting at the 2026-05-21 meeting.

Proposal: director election
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal 1 - Election of Directors. The following directors were elected to serve until the Company’s 2027 annual meeting of stockholders. Director For Withheld Broker Non-Votes Gregg Alton 67,977,943 9,316,514 15,975,718 G. Leonard Baker, Jr. 64,912,506 12,381,951 15,975,718 Joseph K. Belanoff, M.D. 76,965,512 328,945 15,975,718 David L. Mahoney 51,078,278 26,216,179 15,975,718 Joshua M. Murray 76,753,606 540,851 15,975,718 Kimberly Park 70,288,833 7,005,624 15,975,718 Daniel N. Swisher, Jr. 67,594,098 9,700,359 15,975,718 James N. Wilson 72,730,017 4,564,440 15,975,718

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CORCEPT THERAPEUTICS INC shareholders approved Ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-21 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal 2 - The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified. For 92,656,473 Against 569,010 Abstain 44,692 Broker Non-Votes —

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CORCEPT THERAPEUTICS INC shareholders approved Approval of amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan at the 2026-05-21 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal 4 - The amendment to the Corcept Therapeutics Incorporated 2024 Incentive Award Plan was approved. For 53,163,364 Against 23,867,363 Abstain 263,730 Broker Non-Votes 15,975,718

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CORCEPT THERAPEUTICS INC shareholders approved Advisory approval of the compensation of named executive officers at the 2026-05-21 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2026-05-21

Exact text from the filing

Proposal 3 - The compensation of named executive officers was approved, on an advisory basis. For 72,511,429 Against 4,560,385 Abstain 222,643 Broker Non-Votes 15,975,718

View on SEC.gov

Browse all shareholder votes →

CORCEPT THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001628280-26-038793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.